

Resource Summary Report

Generated by RRID on Aug 3, 2026

4T1-Luc [JCRB]

RRID:CVCL_J239

Type: Cell Line

Proper Citation

RRID:CVCL_J239

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_J239

Proper Citation: RRID:CVCL_J239

Description: Cell line 4T1-Luc [JCRB] is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Malignant neoplasms of the mouse mammary gland

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: 4T1-Luc [JCRB]

Cross References: JCRB:JCRB1447, JCRB:NIHS0696, Wikidata:Q54603537

ID: CVCL_J239

Hierarchy: cvcl_0125

Record Creation Time: 20220427T215055+0000

Record Last Update: 20260802T005616+0000

Ratings and Alerts

No rating or validation information has been found for 4T1-Luc [JCRB].

Warning: Discontinued: JCRB; NIHS0696

Data and Source Information

Usage and Citation Metrics

We found 191 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Meng Y, et al. (2025) Targeted Reprogramming of Tumor Cells by Digoxin-Loaded Immunogenic Nanoparticles Enhances Immunity Against Disseminated Tumor Cells. *Advanced healthcare materials*, e02881.

Li B, et al. (2025) Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics. *Frontiers in immunology*, 16, 1539396.

Wang C, et al. (2023) Ultrasound-responsive low-dose doxorubicin liposomes trigger mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity. *Nature communications*, 14(1), 3877.

Kuang X, et al. (2023) Distinct invasive patterns in situ between estrogen receptor-positive and triple-negative breast cancer through the intraductal tracking of carbon nanoparticles. *International journal of cancer*.

Meng R, et al. (2023) Reverse-QTY code design of active human serum albumin self-assembled amphiphilic nanoparticles for effective anti-tumor drug doxorubicin release in mice. *Proceedings of the National Academy of Sciences of the United States of America*, 120(21), e2220173120.

Lu X, et al. (2023) Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway. *Annals of medicine*, 55(1), 2210845.

Wei M, et al. (2023) Glutathione-Exhausting Nanoprobes for NIR-II Fluorescence Imaging-Guided Surgery and Boosting Radiation Therapy Efficacy via Ferroptosis in Breast Cancer. *ACS nano*, 17(12), 11345.

Guo B, et al. (2023) Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative "cold" triple-negative breast cancer. *Bioactive materials*, 25, 61.

Li T, et al. (2023) Nanoparticle-mediated TRPV1 channel blockade amplifies cancer thermo-immunotherapy via heat shock factor 1 modulation. *Nature communications*, 14(1), 2498.

Vári B, et al. (2023) SREKA-targeted liposomes for highly metastatic breast cancer therapy. *Drug delivery*, 30(1), 2174210.

Luo Z, et al. (2023) All-stage targeted therapy for the brain metastasis from triple-negative breast cancer. *Acta pharmaceutica Sinica. B*, 13(1), 359.

Zhao P, et al. (2023) A Novel Derivative of Curcumol, HCL-23, Inhibits the Malignant Phenotype of Triple-Negative Breast Cancer and Induces Apoptosis and HO-1-Dependent Ferroptosis. *Molecules* (Basel, Switzerland), 28(8).

Wang M, et al. (2023) TLR4 Blockade Using Docosahexaenoic Acid Restores Vulnerability of Drug-Tolerant Tumor Cells and Prevents Breast Cancer Metastasis and Postsurgical Relapse. *ACS bio & med chem Au*, 3(1), 97.

Wang X, et al. (2023) A TMVP1-modified near-infrared nanoprobe: molecular imaging for tumor metastasis in sentinel lymph node and targeted enhanced photothermal therapy. *Journal of nanobiotechnology*, 21(1), 130.

Wang S, et al. (2023) ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway. *bioRxiv : the preprint server for biology*.

Tang Y, et al. (2023) Activated platelets facilitate hematogenous metastasis of breast cancer by modulating the PDGFR- α /COX-2 axis. *iScience*, 26(9), 107704.

Chen Q, et al. (2022) A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy. *Journal of controlled release : official journal of the Controlled Release Society*, 346, 212.

Zhou Z, et al. (2022) Pore forming-mediated intracellular protein delivery for enhanced cancer immunotherapy. *Science advances*, 8(46), eabq4659.

Jiang T, et al. (2022) Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatfrom for epithelial-mesenchymal transition suppression and metastatic tumor treatment. *Journal of nanobiotechnology*, 20(1), 394.

Lin YZ, et al. (2022) miR-4759 suppresses breast cancer through immune checkpoint blockade. *Computational and structural biotechnology journal*, 20, 241.